Tanabe is a 348-year-old Japanese drugmaker that a Boston private equity firm bought and is now converting, asset by asset, into a royalty book. In eight months it has sold its largest product, sold a royalty back to its own licensee, and sold its best pipeline asset.

A pharmaceutical royalty is normally bounded by something. The last-to-expire patent, a fixed number of years from first commercial sale, the loss of regulatory exclusivity, or some later-of formulation combining them. The bound is what makes the stream a finite series, and the finite series is what

On 3 June 2026 Mineralys Therapeutics borrowed money at SOFR plus 5.50 percent in order to stop paying a royalty. The company repurchased all potential future royalty payments due to Tanabe Pharma on lorundrostat for $200 million upfront and up to $100 million on commercial milestones, with Tanabe agreeing

Priority in a royalty financing breaks into two questions. One is vertical. Within a single pool of collateral, who stands on which rung. The other is horizontal. How many pools there are, and where each party sits in each of them. Most practitioners answer the first fluently and skip the

Four royalty streams were originated in five days and not one published a rate. The largest was LEO Pharma taking worldwide rights to dersimelagon from Bain-owned Tanabe Pharma, up to $435M in upfront and near-term milestones plus tiered royalties, on an asset whose NDA has been with the

This piece treats the US side. The Chinese side is treated in the companion note, The Chinese gate. A contractual entitlement leaves. The operating capability does not. A fund organised outside the United States pays a US biotech for a percentage of net sales on a marketed product. It takes

Innoviva is a listed permanent-capital vehicle built on two GSK respiratory royalties. It files as a biopharmaceutical company. It behaves like a fund with an annuity attached, and it is in this series for that reason. A royalty stream it did not buy throws off around $240M a year

The US regime asks where the asset is. The Chinese regime asks who is holding it. For a royalty on ex-China sales, that difference decides whether the stream can be sold at all, and it produces a result the opposite of the one most deal teams assume.

A listed royalty company whose lead royalty is pledged in full, whose second royalty pays its milestones to somebody else, and whose licensee it is suing for the drug back.